TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03709875

Intervention type: DEVICE
Group type: OTHER
Intervention: TR Treatment
Description: A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TR Treatment
Description: A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.
Study: NCT01991197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin matched placebo
Description: Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
Study: NCT00758043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: 750 mg every 8 hours (q8h) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: 750 mg every 8 hours (q8h) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
Study: NCT01991197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide matched placebo capsule
Description: Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks.
Study: NCT03863899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration
Description: 15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVI
Description: Insertion of an aortic valve prothesis through the aorta accessed through femoral artery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI
Description: Insertion of an aortic valve prothesis through the aorta accessed through femoral artery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Additional intraoperative analgesia
Description: Administration of any analgesics during the operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional intraoperative analgesia
Description: Administration of any analgesics during the operation
Study: NCT00758043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 - 1200 mg/day based on body weight for either 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
Study: NCT03863899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Additional postoperative analgesia
Description: Administration of any analgesics within first 24 hours after the operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Additional postoperative analgesia
Description: Administration of any analgesics within first 24 hours after the operation
Study: NCT00004189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT03127592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Combination
Description: Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac
Description: Individual drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: Individual drug
Study: NCT02958137

Intervention type: PROCEDURE
Intervention: Arthroscopic Resection Arthroplasty
Description: Surgical removal of the arthritic joint(s) using a minimally invasive technique.
Study: NCT00758043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000 - 1200 mg/day based on body weight for either 24 or 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 mcg/week for either 24 or 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 mcg/week for either 24 or 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 mcg/week for either 24 or 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: 180 mcg/week for either 24 or 48 weeks
Study: NCT00623155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal IPT in children - Sulfadoxine-pyrimethamine
Description: Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
Study: NCT01330381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: prucalopride~* subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~* subjects with weight \>50 kg: prucalopride 2 mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral solution or oral tablets given once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG 4000
Study: NCT02571361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (1g x 4)
Description: Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (1g x 4)
Description: Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen (400 mg x 4)
Description: Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen (400 mg x 4)
Description: Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (0,5 g x 4)
Description: Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen (200 mg x 4)
Description: Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (x4)
Description: Given in 6 hour intervals the first 24 hours postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (x4)
Description: Given in 6 hour intervals the first 24 hours postoperatively
Study: NCT01589302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative laboratory samples
Description: Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
Study: NCT00605371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine tablet
Description: Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine caplet
Description: Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
Study: NCT02896140

Intervention type: OTHER
Intervention: Type 2 diabetes in WhyWAIT Program
Description: The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
Study: NCT03090737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study: NCT02413255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-020
Description: TAK-020 oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-020 Placebo
Description: TAK-020 placebo-matching oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-020 Placebo
Description: TAK-020 placebo-matching oral solution
Study: NCT01009463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
Study: NCT00605371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine caplet
Description: Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
Study: NCT01840761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herbal drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00739193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amiodarone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amiodarone
Study: NCT01043536

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
Study: NCT04239365

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WLE followed by NBI or NBI followed by WLE (crossover design)
Description: EMR scar is inspected using WLE followed by NBI or vice versa
Study: NCT01144351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04457778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6223
Description: Participants will receive an intravenous (IV) infusion of M6223 at escalated doses every 2 weeks (Q2W) or every 3 weeks (Q3W) on Day 1 of each Cycle (Each cycle is of 14 days) according to the recommendation of the SMC(Safety Monitoring Committee) until the maximum tolerated dose(MTD) has been reached or confirmed disease progression.
Study: NCT01009463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/GW642444 Inhalation Powder
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 Inhalation Powder
Description: Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
Study: NCT04239365

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: WLE followed by NBI or NBI followed by WLE (crossover design)
Description: EMR scar is inspected using WLE followed by NBI or vice versa
Study: NCT03772106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Fresenius
Description: Propolipid 1% : IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevorane
Description: sevorane Quick fill (sevoflurane) : inhalation
Study: NCT01855789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Description: TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab (TCZ)
Description: TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (PBO)
Description: PBO matching to MTX will be administered orally.
Study: NCT03781011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegetarian diet intervention
Description: Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
Study: NCT03178305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do CHANGE
Description: Besides the behavior change programme (Do Something Different)~1. All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~2. patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~3. Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake.
Study: NCT01767129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-45
Description: One capsule twice daily for 14 days
Study: NCT03388125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection Sclerotherapy
Description: 5% ethanolamine oleate group
Study: NCT01767129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule twice daily for 14 days
Study: NCT02166086

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Endoscopy involving advanced imaging techniques
Study: NCT01110720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Davunetide
Description: Davunetide Nasal Spray 30 mg BID IN 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Davunetide
Description: Davunetide Nasal Spray 30 mg BID IN 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Nasal Spray BID IN 52 weeks
Study: NCT04457778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Participants will receive an IV infusion of bintrafusp alfa Q2W on Day 1 of each Cycle (Cycle is 14 days) until confirmed disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6223
Description: Participants will receive an IV infusion of M6223 at escalated doses Q2W on Day 1 of each Cycle (Each cycle is of 21 days) according to the recommendation of the SMC until the MTD has been reached or confirmed disease progression.
Study: NCT02459925

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT- Mental Health Program
Description: Manualized Stress Management class; brief individual behavioral counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOMS GROW
Description: MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
Study: NCT02327780

Intervention type: OTHER
Group type: OTHER
Intervention: FODMAP diet
Study: NCT03388125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-butyl-2-cyanoacrylate
Description: N-butyl-2-cyanoacrylate injection group
Study: NCT03251976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: informational video
Study: NCT04133428

Intervention type: DRUG
Intervention: Sacubitril-Valsartan
Description: Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made.
Study: NCT03062150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone
Description: Fludrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone
Description: Fludrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: D-Cycloserine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: D-Cycloserine
Study: NCT02874066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTV/r/OBV/DSV
Description: Viekirax/Exviera for 12 weeks
Study: NCT04675242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 4251
Description: NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily